

Cell Line	ALK Status	MYCN status	IC <sub>50</sub> (nM)		Fold
			Crizotinib	PF-06463922	
<b>NB-1643</b>	R1275Q	Amplified	<b>308.4 ± 80.7</b>	<b>6.1 ± 0.3</b>	51
<b>LAN-5</b>	R1275Q	Amplified	<b>320.4 ± 38.5</b>	<b>16.8 ± 4.3</b>	19
<b>SH-SY5Y</b>	F1174L	Non-amplified	<b>625.1 ± 55.7</b>	<b>16.5 ± 1.2</b>	38
<b>NB-SD</b>	F1174L	Amplified	<b>473.6 ± 119</b>	<b>12.7 ± 1.3</b>	38
<b>COG-N-415</b>	F1174L	Amplified	<b>379.5 ± 27.3</b>	<b>14.6 ± 6.2</b>	26
<b>KELLY</b>	F1174L	Amplified	<b>898.8 ± 33.5</b>	<b>26.6 ± 1.2</b>	34
<b>Felix</b>	F1245C	Non-amplified	<b>814.0 ± 119</b>	<b>21.8 ± 3.2</b>	37
<b>NB-1</b>	Amplified wt	Amplified	<b>256.4 ± 73.3</b>	<b>5.2 ± 1.4</b>	49
<b>NCI-H3122</b>	EML4-ALK, v1	Unknown	<b>349.5 ± 25.3</b>	<b>2.8 ± 0.4</b>	125
<b>NB-EBc1</b>	Wild-type	Non-amplified	<b>3,841 ± 1081</b>	<b>&gt;3,841</b>	-
<b>SK-N-BE(2)-C</b>	Wild-type	Amplified	<b>4,503 ± 58.6</b>	<b>&gt;4,503</b>	-

**Supplemental Table 1.**

**PF-06463922 is potent against ALK-mutated NB cell lines *in vitro*.**

Mean (n=3) IC<sub>50</sub> values (± SD) for crizotinib and PF-06463922 are listed for 10 NB cell lines harboring the indicated ALK aberrations, plus one NSCLC cell line (NCI-H3122). Fold increases in the IC<sub>50</sub> values with crizotinib over those measured for PF-06463922 are also listed in the right-most column.